An invasive strategy including percutaneous coronary intervention (PCI) improves clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and in high-risk patients with non-ST-segment elevation acute coronary syndrome (NSTEACS).
1,2The femoral approach (TFA) is the preferred and most widely used percutaneous access site in most cardiac catheterisation laboratories worldwide. However, being a relatively deep and terminal vessel, the femoral artery may expose the patient to frequent bleeding and vascular complications, 3,4 especially in the setting of acute coronary syndrome (ACS) where potent antithrombotic drugs are frequently used. 5,6 Since its initial description as a safe and feasible access route for cardiac catheterisation, 7,8 the transradial access (TRA) has increasingly been used for PCI. The main advantage over the TFA is a reduced risk of access site bleeding and major vascular complications, particularly in the presence of multiple and more powerful antiplatelet and antithrombotic agents.9 This is mainly ascribed to the more favourable anatomy of the radial artery that runs superficially, separated from major neurovascular structures, thus allowing shorter times to haemostasis and ambulation as compared with the TFA.
10More recently, the radial approach has been shown to confer mortality benefits for STEMI patients and a reduction in mortality, myocardial infarction (MI) and stroke for patients undergoing the procedure at high-volume radial centres.
11-13Reported access failure for radial procedures in primary PCI (PPCI) is low with an access crossover rate between 3.8 % 14 and 9.6 % 13 with negligible time delay by expert operators. There are several reasons leading to failure -inability to cannulate, severe radial artery spasm (RAS) and anatomical variations. In some of these difficult transradial cases, ulnar artery cannulation has been proposed as a reasonable and useful alternative to the TRA if performed by an experienced radial operator, before crossover to the TFA.
15,16
Bleeding Complications in Acute Coronary SyndromePeri-PCI procedural bleeding complications have been consistently associated with worse outcomes and increased short-and longterm mortality. 6,17 Access site-related bleeding, accounting for as many as 30-50 % of all causes of bleeding in patients with ACS, has repeatedly been found to be the major contributor for bleeding events. 9,[18][19][20] Due to the firm link between bleeding, ischaemic events and mortality, more attention has recently been focused on bleeding avoidance strategies.21 Despite the development of new more potent, selective and safe antithrombotics, the use of TRA remains likely the best way to significantly influence access site-related bleeding risk. [22][23][24][25] Recently, the REgistro regionale AngiopLastiche dell'Emilia-Romagna (REAL) Registry of 11,068 STEMI patients undergoing PPCI, showed that TRA was associated with a decreased two-year mortality rate compared with the traditional TFA (8.8 versus 11.4 %, hazard ratio ...